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Background: Current evidence suggests that initiation, growth, and invasion of cancer are driven by a small
population of cancer stem cells (CSC). Previous studies have identified CD44+ cells as cancer stem cells in head
and neck squamous cell carcinoma (HNSCC). However, CD44 is widely expressed in most cells in HNSCC tumor
samples and several cell lines tested. We previously identified a small population of CD24+/CD44+ cells in HNSCC.
In this study, we examined whether this population of cells may represent CSC in HNSCC.
Methods: CD24+/CD44+ cells from HNSCC cell lines were sorted by flow cytometry, and their phenotype was
confirmed by qRT-PCR. Their self-renewal and differentiation properties, clonogenicity in collagen gels, and response
to anticancer drugs were tested in vitro. The tumorigenicity potential of CD24+/CD44+ cells was tested in athymic
nude mice in vivo.
Results: Our results show that CD24+/CD44+ cells possessed stemness characteristics of self-renewal and differentiation.
CD24+/CD44+ cells showed higher cell invasion in vitro and made higher number of colonies in collagen gels compared
to CD24-/CD44+ HNSCC cells. In addition, the CD24+/CD44+ cells were more chemo-resistant to gemcitabine and
cisplatin compared to CD24-/CD44+ cells. In vivo, CD24+/CD44+ cells showed a tendency to generate larger tumors
in nude mice compared to CD24-/CD44+ cell population.
Conclusion: Our study clearly demonstrates that a distinct small population of CD24+/CD44+ cells is present in HNSCC
that shows stem cell-like properties. This distinct small population of cells should be further characterized and may
provide an opportunity to target HNSCC CSC for therapy.
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Squamous cell carcinoma of head and neck (HNSCC) is
a heterogeneous disease [1]. Although recent advances
in treatment have improved quality of life, overall 5 year
survival rates have not improved significantly [2]. HNSCC
frequently shows local recurrence and metastasis after the
initial treatment of the primary tumor [3]. Mortality from
this disease remains high because of the development
of metastases and therapy-resistant local and regional* Correspondence: raj.puri@fda.hhs.gov
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reproduction in any medium, provided the orrecurrences [1]. Progress in treatment and prognosis for
HNSCC has been limited and the molecular mechanisms
of HNSCC escape from chemo- and/or radiation therapies
remain mostly unknown.
Recent evidence suggests that small populations of
tumor-initiating cells or cancer stem cells (CSC) are re-
sponsible for initiation, tumorigenesis, progression, and
metastasis [4]. CSCs undergo self-renewal and differenti-
ation to yield phenotypically diverse non-tumorigenic and
tumorigenic cancer cells [4,5]. CSCs have been identified,
isolated, and characterized in various types of cancers,
such as leukemia [6], brain tumor [7], colorectal cancer
[8], ovarian cancer [9], bladder cancer [10], pancreatic
cancer [11] and others. It has been postulated that CSCs. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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thus leading to disease relapse. Therefore, an important
goal of therapy could be to identify and kill this CSC
population. If CSCs can be identified prospectively and
isolated, then we should be able to identify new diagnostic
markers and potential therapeutic targets.
HNSCCs are heterogeneous in cellular composition.
A CD44+ subpopulation of cells with CSC properties
was first identified in HNSCC [12]. These CD44+ cells
express a high level of the BMI1 gene, which has been
demonstrated to play a role in self-renewal and tumori-
genesis [13,14]. In addition to CD44, other putative stem
cell markers reported to be present in HNSCC cell lines
include CD29 and CD133, but the proportion of cells
expressing these markers differed from one cell line to
the other [15]. Additional studies indicate that ALDH
activity may represent a more specific marker for CSCs
in HNSCC [16,17]. It is unknown if cancer stem cell
markers are tumor specific for the tissue of origin or
for the niche where the tumor is growing [18].
The CD24 gene has raised considerable interest in
tumor biology. A large body of literature suggests a role
for CD24 in tumorigenesis and tumor progression. CD24
expression causes the acquisition of multiple cellular prop-
erties associated with tumor growth and metastasis [19].
Recent studies have identified CD24 as a marker in cancer
stem cells in several cancers, including pancreatic cancer
[11], colorectal cancer-derived cell lines [8], and ovarian
cancer [9]. Cancer stem cell immunophenotype studies
in oral squamous cell carcinoma indicated that patients
with CD24 and CD44 double-positive cells showed the
lowest overall survival rate compared to other immuno-
phenotypes [20]. In our previous studies, we also found
that a small population of CD24+/CD44+ cells existed in
HNSCC [21]. Whether or not CD24+/CD44+ cells repre-
sent a potential phenotype of cancer stem cells in HNSCC
remains to be determined.
In the present study, we have isolated the CD24+/CD44+
population from HNSCC cell lines and determined
whether this cell population has cancer stem cell
properties by a variety of different approaches. We
demonstrate that the CD24+/CD44+ population indeed




HNSCC cell line A253 (ATCC®HTB-41) was obtained from
American Type Culture Collection (ATCC, Manassas, VA).
HNSCC cell line KCCT873 was obtained from Yokohama
City University Hospital [22]. A253 cells were established
from tumor originated from submaxillary salivary gland.
KCCT873 cells were originated from tongue tumor. A253
cells were grown in McCoy’s Modified Medium, andKCCT873 cells in RPMI 1640 medium. Cell culture media
were supplemented with 10% fetal bovine serum and 1%
penicillin/streptomycin (Lonza, Walkersville, MD). The
cells were maintained at 37°C in a humidified atmosphere
containing 5% CO2.
Fluorescent-activated cell sorting and flow
cytometry analysis
Cell sorting by flow cytometry was performed by Mr.
Howard Mostowski at the Flow Cytometry Core facility,
Center for Biologics Evaluation and Research, FDA. Cells
were labeled with mouse anti-human CD44-PE (Millipore,
Temecula, CA) and mouse anti-human CD24-FITC (Santa
Cruz Biotech, Santa Cruz, CA) antibodies. The top or
bottom cells in the 0.5 to 1 percentile fluorescence intensity
of each CD24+/CD44+ and CD24-/CD44+ subpopula-
tions were sorted and collected separately for further
experiments.
For flow cytometric analysis of other markers, cells
(106 cells/ml) were resuspended and incubated with
various antibodies, CD29-APC, CD73-APC, and CD90-
PerCP-Cy5.5 (eBioscience - www.ebioscience.com), CD24-
FITC (Santa Cruz Biotech), and CD44-PE (Millipore),
according to the manufacturer’s instructions for 30 min
on ice, washed with PBS three times, and fixed with 1%
paraformaldehyde for later analysis. For controls, relevant
isotype control antibody (eBioscience) and no antibody
was used in parallel. Data were analyzed using FlowJo
software (Tree Star Inc., Ashland, OR).
Real-time PCR
For qRT-PCR, total RNAs was extracted by Trizol reagent
according to the manufacturer’s instructions (Invitrogen,
Carlsbad, CA). The 1st strand cDNA was synthesized from
1 μg of total RNA using Superscript II Reverse Transcript-
ase (Invitrogen) according to manufactures specifications.
The resulting cDNA was amplified by using gene-specific
primers. The primer sequences for each tested gene are
listed in Additional file 1: Table S1. For amplification,
samples were prepared with SsoAdvancedTM SYBR® Green
Supermix (Bio-Rad) following the manufacture’s protocol,
and run on a Bio-Rad CFX96 TouchTM Real-Time Detec-
tion System. Buffer only and no template were included
in each assay run as controls. All samples and controls
were run in triplicate. Gene-specific amplification was
normalized to β-Actin and relative fold change was cal-
culated following the manufacture’s protocol (Bio-Rad).
Cell proliferation assay
One thousand sorted cells per well were cultured in
quadruplicate in 96-well plates for the indicated period
of time. Cell proliferation was detected by using CellTi-
ter-Glo® Luminescent Cell Viability Assay kit (Promega,




















































































Figure 1 Expression of CD24 and CD44 in A253 HNSCC cells. (A)
Flow cytometric analysis of CD24+ and CD44+ cells in A253 HNSCC
cell line. Dual staining of A253 HNSCC cells indicate that CD24+/CD44+
subpopulation is ~6%, while CD24-/CD44+ subpopulation is >93% in
the whole cell population. qRT-PCR analysis of stemness-related genes
in FACS-sorted CD24+/CD44+ and CD24-/CD44+ cells derived from
A253 (B) and KCCT873 (C) tumor cells. Data represent log2 mean
fold changes in gene expression ± SD of triplicate determinations
in CD24+/CD44+ compared to CD24-/CD44+ subpopulations from
both cell lines. P values for two genes, BMI1 and Nanog, in two cell
lines are shown.
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Devices, Sunnyvale, CA) with 500 ms integration. Ex-
perimental background was determined by using empty
wells with medium.
Colony-forming assay
Collagen type I gels were prepared with cell culture
medium to make final collagen concentration of 2 mg/mL
(pH = 7.0) [23]. For cell cultures within collagen gels,
1.5 mL cell suspension (500 cells/mL) was mixed with
1.5 mL of collagen solution. The mixture was plated in
six-well plates, and placed in 37°C incubator for gelation.
After gelation, the collagen gels were overlaid with 3 mL
of complete medium and incubated in a humidified
atmosphere containing 95% air and 5% CO2. Cells were
cultured for six days. Cell colonies were visualized with
Coomassie Blue solution staining (0.5% Coomassie Brilliant
Blue G250, Bio-Rad), and visible colonies were counted.
Assays were performed in triplicate.
Matrigel invasion assay
Cell invasion was studied by using BD BioCoat Matrigel
invasion chambers (BD Biosciences; 24-well, 8 μm pore
size) with 10% fetal bovine serum as a chemo attractant,
and following the manufacture’s protocol. Briefly, one
thousand cells were loaded into the chamber and incu-
bated for 24 to 72 hrs at 37°C. Noninvasive cells were
removed from the upper surface of the membrane with
a cotton swab, and cells on the bottom surface of the
membrane were fixed and stained with H&E. Cells in
five random fields per well were counted. The experiments
were performed in duplicate.
Drug sensitivity assay
Following cell sorting, both CD24+/CD44+ and CD24-/
CD44+ cells were cultured for 2 days to eliminate dam-
aged cells caused by the sorting process. Cells were
then plated at a density of 1 × 103/well in 96-well plates.
Chemotherapeutic reagents, Gemcitabine or Cisplatin,
were added to the cells at gradually increasing concen-
trations. The cells were cultured for 72 hrs, and the cell
viability was determined by CellTiter-Glo® Assay (Promega,
Madison, WI) according to the manufacturer’s protocol.
Tumor xenograft studies
Animal studies were conducted under a CBER ACUC-
approved protocol in accordance with the principles and
procedures outlined in the NIH Guide for the Care and
Use of Laboratory Animals. Female athymic nude immu-
nodeficient mice between 4-to 6-week-age were obtained
from the NCI Animal Facility (NCI-Frederick). Before
injection, cells were re-suspended in a 1:1 mixture of
Matrigel (BD Biosciences) and PBS. A 100-μl cell sus-
pension containing 100, 1,000, or 10,000 sorted CD24+and CD24-cells was subcutaneously injected into the
dorsal flank of each mouse. For the control groups,
mice received 100 μl injections of the parent unsorted
cells in corresponding concentrations. Tumor size (major
axis × the minor axis) was measured weekly after tumor
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times. At the end of the experimental period, tumor
tissues were collected and fixed in formalin for further
immunohistochemical studies.
Immunohistochemical studies of HNSCC tumor tissues
Immunohistochemical (IHC) studies of tumor sections were
performed on formalin-fixed, paraffin-embedded tumors
isolated from tumor xenografts in the study. Tissue
sections were deparaffinized by xylene, and re-hydrated
with sequential washes of 100%, 75%, and 50% ethanol,
and PBS. For antigen retrieval, slides were placed in
50 mM citrate buffer pH 6.0 (Vector Lab, CA), boiled
for 5 min, and stayed in the buffer for 15 min. Endogenous
peroxidase activity was inhibited with 3% hydrogen perox-
idase in PBS. Non-specific binding was blocked with 2.5%

































Figure 2 Differentiation of CD24+/CD44+ cells. (A) A253 CD24+ HNSCC ce
simple growth model in which CD24+ cells divide and switch to a CD24-state.
one, two and three, from left to right panels. (B) Flow sorted CD24+ cells were
CD24-cells. Day 0 indicates the day cells were sorted by CD24 expression. The1 hr. Tissue sections were incubated with various anti-
bodies, CD24 and CD44 (Millipore), or isotype control
(IgG) (Sigma) overnight at 4°C. Immunodetection was
performed using ABC staining systems according to
manufacturer’s instructions (Santa Cruz Biotech). All
sections were counterstained with haematoxylin. After
dehydration with washes of 95% and 100% ethanol and
xylene, tissue sections with permanent mounting medium
were covered with glass coverslips, and viewed by light
microscope. H&E staining was also performed on the
section from each tumor tissue sample.
Statistical analysis
Statistical analyses were performed by paired Student’s
t-test between two groups. Data were presented as









lls differentiate into CD24-cells. Population dynamics modeled by a
Flow cytometry plots illustrate the sorted CD24+ cell populations at week
monitored for 3 weeks in cell culture for their ability to convert into





Figure 3 Cell proliferation assay. Cells were cultured in quadruplicate
in a 96-well plate at a density of 1000 cells/per well, and proliferation
was measured by Cell Titter-Glo® cell viability assay. Growth curve of
CD24+/CD44+ and CD24-/CD44+ subpopulations of A253 cells (A)
and KCCT873 cells (B) are shown. Data represent mean ± SD of
triplicate determinations. P value is shown for day 5 time point.
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including animal experiments.
Results
Isolation and characterization of CD24+/CD44+ cells in
HNSCC cell lines
To determine the percentage of the putative cancer stem-
like cells in the HNSCC cell population, cell suspensions
from cell lines A253 and KCCT873 were analyzed and
sorted for cell surface markers CD24 and CD44 by
flow cytometry. Two phenotypic subpopulations were
separated. CD24+/CD44+ cells were only ~5-8% in
whole cell population. In contrast, CD24-/CD44+ cells
were >90% in whole cell population of both HNSCC
cell lines (Figure 1A).
We next investigated the expression of known “stem-
ness” genes in the isolated CD24+/CD44+ and CD24-/
CD44+ subpopulations by real-time RT-PCR technology.
We tested expression of six genes including ALDH1,
BMI1, CD133, Nanog, Oct3/4, and Sox2. BMI1 and
Nanog genes showed a significantly higher expression in
CD24+/CD44+ compared to CD24-/CD44+ subpopula-
tions from both HNSCC cell lines. However, there was
no significant difference in ALDH1 expression between
CD24+/CD44+ and CD24-/CD44+ subpopulations from
both cell lines (Figure 1B and C). CD133 was only
expressed in one cell line (KCCT873) at a very low level
and did not show a clear difference between two sub-
populations of cells (data not shown). A253 cells did not
show any expression of CD133 gene. The expression of
Oct3/4 and Sox2 was absent in both cell subpopulations
in both cell lines (data not shown).
Cellular properties of CD24+/CD44+ cells in vitro
To explore the self-renewal and differentiation capacity
of CD24+/CD44+ cells, the purified CD24+/CD44+ cells
were cultured in vitro for 3 weeks, and variations in
CD24 expression were examined by flow cytometry.
We found that the proportion of CD24+/CD44+ cells
dramatically declined in a time dependent manner in
the CD24+/CD44+ sorted population of cells. CD24+
cells in CD24+/CD44+ population decreased to ~62%
one week after culture and continued to decrease to
28% two weeks after cell culture. The proportion of the
CD24+/CD44+ cells returned to similar presorting level
(< 10%) after three weeks culture. In contrast, the pro-
portion of CD24-/CD44+ cells in the cell population
gradually increased from ~30% at the first week to ~86%
after three weeks, indicating that the CD24+/CD44+ cells
give rise to CD24-/CD44+ cells (Figure 2A and B).
Cell proliferation assays indicated that the growth
rate of CD24+/CD44+ cells was slightly lower com-
pared to CD24-/CD44+ cells for up to 5 days after cell
sorting (Figure 3A and B). These results indicate thatCD24+/CD44+ cells show asymmetric division-like pro-
liferation pattern, indicating the self-renewal and differ-
entiation potential to produce heterologous descendent
CD24-/CD44+ cells in culture.
We next investigated the invasion ability of CD24+/
CD44+ and CD24-/CD44+ subpopulations by matrigel
invasion assays. We observed that the number of invading
cells in the CD24+/CD44+ cells was significantly higher
compared to CD24-/CD44+ cells, indicating that CD24+/
CD44+ cells have higher invasion ability compared to
CD24-/CD44+ cells (p < 0.02 for A253 and p < 0.01 for
KCCT873 compared to CD24-/CD44+ cells) (Figure 4A).
The colony-formation capacity of CD24+/CD44+ and
CD24-/CD44+ subpopulations was also tested. Our results
indicate that CD24+/CD44+ cells form significantly higher
number of colonies compared to CD24-/CD44+ cell sub-








































Figure 4 Cell invasion and clonogenic assays. (A) Matrigel invasion activity of CD24+/CD44+ and CD24-/CD44+ flow cytometry-sorted cells from
HNSCC cell lines. The number of cells invading through the Matrigel was assessed at 24 hr. (B) Colony-forming assay with FACS-sorted CD24+/CD44+
and CD24-/CD44+ cells. The CD24+/CD44+ cells show significantly higher number of colonies. P values for invasion and clonogenic assays are shown
in the figure.
Han et al. BMC Cancer 2014, 14:173 Page 6 of 11
http://www.biomedcentral.com/1471-2407/14/173CD24+ cells show higher drug resistance to
chemotherapeutic agents in vitro
Cisplatin (cis-diammine-dichloroplatinum (II)) is used for
treatment of a wide range of cancers, including head &
neck tumors. Cisplatin often leads to an initial thera-
peutic success associated with partial response or disease
stabilization [24]. Gemcitabine is a nucleoside analog
displaying a wide spectrum of antitumor activity [25].
Although both drugs have been used for chemothera-
peutic treatment of patients with head & neck tumors,
many patients are intrinsically resistant to these drugs
[24]. Recent studies have indicated that cancer stem
cell phenotypes are associated with drug resistance to
chemotherapeutic drugs [26,27]. To evaluate the drug
resistance properties of FACS sorted HNSCC cells,
CD24+/CD44+ and CD24-/CD44+ cells were grown and
treated with various concentrations of either cisplatin or
gemcitabine for 72 hours, and then cell survival was
assessed by determining cell viability. CD24+/CD44+
cells seem to show small but significantly higher drug
resistance to either chemotherapeutic agent when com-
pared to CD24-/CD44+ cells (Figure 5). For example,CD24+/CD44+ cells showed higher survival rate (53.5%)
compared to CD24-/CD44+ cells (40%) when treated
with 1000 nM cisplatin (p < 0.01) (Figure 5A). Similarly,
CD24+/CD44+ cells showed > 10% higher survival
rate (37%) compared to survival rate (26%) of CD24-/
CD44+ cells when treated with 10 nM gemcitabine
(p < 0.01) (Figure 5B).
Tumorigenicity of CD24+/CD44+ and CD24-/CD44+
subpopulations
We next evaluated whether the two subpopulations
(CD24+/CD44+ and CD24-/CD44+) of HNSCC cells
were endowed with differential tumorigenic potential.
Several independent experiments were performed with
two different HNSCC cell lines. The two phenotypic
subpopulations of cells, CD24+/CD44+ and CD24-/CD44+,
were sorted by flow cytometry, suspended in a Matrigel
mixture (1:1), and then S.C. injected into athymic nude
mice. The tumor size was measured weekly for 9 weeks,
at which time animals were sacrificed. When minimal
(1 × 102) to maximal (1 × 104) numbers of cells per mouse

















Figure 5 Sensitivity of CD24+/CD44+ and CD24-/CD44+ cells to cisplatin and gemcitabine anticancer drugs. Flow cytometry sorted cells
were exposed to cisplatin (A), and gemcitabine (B) at increasing concentrations for 72 hr, followed by cell viability measurement by Cell Titter-Glo® Cell
Viability Assay. Differences in drug resistance between CD24+/CD44+ and CD24-/CD44+ cells were calculated. All experiments were performed in
triplicate and data are shown as mean ± SD. Data in inset show statistical significance at p < 0.01 for both treatments.
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the size of tumor generated by CD24+/CD44+ cells was
significantly larger than the size of the tumors from
CD24-/CD44+ or unsorted control cells (Figure 6) indi-
cating CD24+/CD44+ cells are highly aggressive.
Immunohistochemical staining for CD24 and CD44
on tumor tissues isolated from tumor xenografts at the
end of the study were performed to determine whether
CD24+/CD44+ CSC maintained their phenotype at the
end of the experiment. Upon H&E staining, A253 cells
showed submaxillary salivary gland features since these
cells originated from submaxillary salivary gland tumor.
KCCT873 cells showed similar features. By IHC, strong
positive staining for CD24 was observed on the surface
of salivary gland appearing structure in xenograft tu-
mors derived from both cell lines. In addition, strong
positive staining for CD44 was observed not only on
the surface of salivary gland appearing structures, but
also on the dense carcinoma cells within the tumor
mass as well (Figure 7). Since xenograft tumors generatedfrom both CD24+/CD44+ and CD24-/CD44+ cells showed
the similar immunohistochemical staining, we hypothe-
sized that the CD24+/CD44+ cells may have been gener-
ated during the in vivo tumor growth from CD24-/CD44+
cell subpopulation.
Flow cytometry analysis of additional stemness cell markers
To investigate whether other putative stem cell markers
were expressed in HNSCC cells, the mesenchymal stem
cell markers, CD29 (β1-integrin), CD73 (5′-nucleotidase),
CD90 (Thy-1), and CD105 (Endogin) were selected and
analyzed by flow cytometry. CD29 expression showed the
strongest correlation with the CD44 expression. Almost
all cells (99.6%) were CD29 and CD44 double-positive.
Only ~6% of the cells were CD29+ and CD24+, the same
percentage found for CD24+/CD44+ cells (Figure 8A).
CD73 also showed a strong correlation with CD44 expres-
sion. Approximately 92% of the cells were CD73 and
CD44 double-positive, while only ~6% of the cells were





Figure 6 In vivo tumorigenicity of CD24+/CD44+ and CD24-/
CD44+ HNSCC cells. Athymic nude mice were injected s.c. 1000
cells in 100 μl matrigel containing either CD24+/CD44+, CD24-/
CD44+, or unsorted cells (control). Each group had five animals and
experiment was repeated several times. (A) Tumors were generated
from A253 cells; and (B) KCCT873 cells. Tumor sizes were measured
once a week and shown as mean ± SD. P value is shown for week 9
groups comparing CD24+/CD44+ and CD24-/CD44+ HNSCC tumors.
Tumor generated from 
CD24+ selected cells





Figure 7 Immunohistochemical analyses of CD24 and CD44 in
tumors generated from CD24+/CD44+ and CD24-/CD44+ HNSCC
cells. Both CD24 and CD44 show cell surface staining. CD24 was only
present on the salivary gland type cells and show membrane and
cytoplasmic staining. CD44 show strong positive reactions not only in
salivary gland type cells, but also in most tumor cells. Tumors generated
from CD24+ and CD24- cells showed the similar immunohistochemical
staining patterns for CD24 and CD44.
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correlation with either CD24 or CD44 expression (data
not shown).
Discussion
We have identified and characterized a distinct CD24+
subpopulation in the CD44+ population of HNSCC tu-
mors. These CD24+/CD44+ cells derived from HNSCC
cell lines displayed several features typically seen in
cancer stem cells, including the ability to differentiate
and self-renewal. CD24+/CD44+ cells were more pro-
liferative and invasive in vitro and more tumorigenic
in vivo forming larger tumors in immunodeficient mice
compared to its counterpart CD24-/CD44+ cells. In
addition, CD24+/CD44+ cells were slightly more resistant
to chemotherapeutic agents compared to CD24-/CD44+
cells. These findings indicate that a distinct CD24+/CD44+
subpopulation may represent CSC or tumor initiating cells
in HNSCC.We confirmed the stemness feature of CD24+/CD44+
cells by showing that CD24+/CD44+ cells express higher
levels of BMI1 and Nanog genes compared to CD24-/
CD44+ cells. BMI1 has been shown to play a role in
the self-renewal of hematopoietic stem cells [14] and is
considered a stem cell related gene. BMI1 has also been
implicated in tumorigenesis, primarily in leukemias [13],
and in several human cancers including HNSCC [12].
Similarly, Nanog gene has been shown to be associated
with stemness of human embryonic stem cells [28]. These
results support our finding that CD24+/CD44+ cell sub-
populations are indeed CSC in HNSCC. Our data also
show a strong correlation between CD29 (β1-integrin)
and CD44 expression in HNSCC. More than 99% cells
were CD29 and CD44 double-positive, indicating CD24+/
CD44+ cells were also CD29+. Recently, a subpopulation
of cells (Lin−/CD29+/CD24+) isolated from mouse mam-
mary cells was identified as mammary stem cells [29]. It is
also reported that CD24 expression positively associated
with salivary gland cancer stage III/IV [30]. These authors
showed that double positive (CD24+/CD44+) cells may
































Figure 8 Representative flow cytometry plots analyzing expression of CD29, CD24, CD44, and CD73 in A253 HNSCC cells. (A)
Co-expression of CD29 with CD44 and CD24. (B) Co-expression of CD73 with CD44 and CD24.
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identified as a putative marker for cancer stem cells in
many cancers including HNSCC, we did not find a sig-
nificant difference of these genes between CD24+/CD44+
and CD24-/CD44+ cell populations. In addition, Oct3/4,
Sox2 and CD133 were not consistently expressed in these
cells. It is possible that different tumor cell lines, types
and origin of tumors may have different phenotype of
HNSCC CSCs.
Previous studies have demonstrated that CD24 is in-
volved in cell adhesion and metastatic tumor spread
[19,31,32], and may be one of the cancer stem cell markers
expressed in various cancer cell lines [33]. Consistent with
our observations, a highly tumorigenic subpopulation of
cells with CD44+/CD24+/ESA + phenotype was identified
as cancer stem cells in pancreatic cancer [11]. Although
this phenotype was only 0.2 to 0.8% in the whole pancre-
atic cancer cell population, it had a 100-fold increased
tumorigenic potential compared with other phenotypes
[11]. Similarly, a CD24+/CD44+ cancer stem cell subpop-
ulation has been identified in solid tumors and cancer
cell lines in both colorectal and ovarian cancers [8,9].
CD24 has been shown to be related to invasiveness and
differentiation of colorectal adenocarcinoma [34]. CD24
has also been identified as one of the cancer stem cellmarkers in human malignant mesothelioma cells [35].
These studies suggest that CD24 is both a marker of
tumor aggressiveness and a promoter of metastatic tumor
growth. Thus, targeting CD24 may offer new approach for
therapy of human cancer including HNSCC.
Similar to CD24, previous studies have identified CD44,
BMI1 and ALDH1 as putative markers for CSC in head
and neck squamous cell carcinomas [12,16,17]. CD44 has
also been identified as one of the CSC markers in various
other cancer types [8,11,12,20,33]. CD44 was not only
found to be constitutively expressed in the HNSCC cell
lines, but also abundantly expressed in head and neck
carcinomas [21,36,37]. HNSCC tumors can arise from
many location of the upper aerodigestive tract, including
the nasal cavity, sinus cavities, oral cavity, pharynx, or
larynx. The various locations associated with malignant
transformation implicated a wide-range of tumors rep-
resentative of the anatomic locations [38]. Although
multiple cell surface markers have been identified as
cancer stem cell markers, it is clear that no marker can be
used universally to identify cancer stem cells in HNSCC.
Expression of various CSC markers shows great variations
between different tumor types, even in the same tumor
but different subtypes [33]. CD24+/CD44+ subpopulation
identified in our study may represent a new subtype of the
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malignant neoplasms.
It was noted that the tumors generated by both CD24+/
CD44+ and CD24-/CD44+ cells were positive for CD24+/
CD44+ in IHC studies. IHC staining of xenograft tumor
tissues showed positive staining for CD24 on the salivary
gland appearing structures. In addition, strong positive
staining for CD44 was observed not only on the surface of
salivary gland appearing structure, but also on the carcin-
oma cells within the tumor mass. There are two possible
explanations for the presence of CD24+/CD44+ tumor
cells from CD24-/CD44+ tumors. First, CD24+/CD44+
cells may have been generated during the in vivo tumor
growth from CD24-/CD44+ cell population. This hypoth-
esis is supported by recent publications that indicate that
normal and neoplastic nonstem cells can spontaneously
convert to a stem-like state. Chaffer et al., showed that
CD44hi cells can differentiate into CD44lo/CD24+/ESA−
and CD44lo/CD24+/ESA + progeny, and CD44lo cells
can spontaneously convert to CD44hi cells [39]. Second,
since CD24+/CD44+ and CD24-/CD44+ HNSCC cells
were sorted by FACS technology, we cannot rule out
the possibility of undetectable residual CD24+/CD44+ cells
contaminating the CD24-/CD44+ cell population, which
resulted in CD24+/CD44+ cells within the xenograft
tumors, although this was considered a remote possibility.
Conclusion
We have demonstrated that HNSCC contain a distinct
CD24+/CD44+ cell subpopulation that possesses cancer
stem cell-like properties. CD24+/CD44+ cells are able to
self-renew, differentiate into different phenotypes, initi-
ate and develop tumors in athymic nude mice faster.
Identification of cancer stem cells may provide novel
insights into the development of new therapeutic ap-
proaches for HNSCC.
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